+

WO1999001117A3 - Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins - Google Patents

Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins Download PDF

Info

Publication number
WO1999001117A3
WO1999001117A3 PCT/EP1998/004066 EP9804066W WO9901117A3 WO 1999001117 A3 WO1999001117 A3 WO 1999001117A3 EP 9804066 W EP9804066 W EP 9804066W WO 9901117 A3 WO9901117 A3 WO 9901117A3
Authority
WO
WIPO (PCT)
Prior art keywords
activators
inhibitors
hsf
heat shock
kappab
Prior art date
Application number
PCT/EP1998/004066
Other languages
French (fr)
Other versions
WO1999001117A2 (en
Inventor
Maria Gabriella Santoro
Antonio Rossi
Giuliano Elia
Original Assignee
Consiglio Nazionale Ricerche
Maria Gabriella Santoro
Antonio Rossi
Giuliano Elia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche, Maria Gabriella Santoro, Antonio Rossi, Giuliano Elia filed Critical Consiglio Nazionale Ricerche
Priority to JP50633999A priority Critical patent/JP2002507981A/en
Priority to EP98940106A priority patent/EP1003492A2/en
Priority to AU88545/98A priority patent/AU8854598A/en
Priority to CA002294764A priority patent/CA2294764A1/en
Publication of WO1999001117A2 publication Critical patent/WO1999001117A2/en
Publication of WO1999001117A3 publication Critical patent/WO1999001117A3/en
Priority to US10/742,523 priority patent/US20050020687A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibitors of the NF-kB factor and corresponding pharmaceutically acceptable derivative compounds to be used as activators of the HSF factor for the transcription and translation of heat shock genes, with production of hsp70, particularly with anti-inflammatory, anti-proliferative, immuno-suppressive, cytoprotective and antiviral activity.
PCT/EP1998/004066 1996-01-14 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins WO1999001117A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50633999A JP2002507981A (en) 1997-07-01 1998-07-01 NF-κB factor inhibitor as HSF activator and heat shock protein inducer
EP98940106A EP1003492A2 (en) 1997-07-01 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
AU88545/98A AU8854598A (en) 1997-07-01 1998-07-01 Inhibitors of the nf-(k)b factor as activators of hsf and inducers of heat shockproteins
CA002294764A CA2294764A1 (en) 1997-07-01 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
US10/742,523 US20050020687A1 (en) 1996-01-14 2003-12-19 Methods of treating inflammatory and viral disorders by administering cyclopentenone compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000392A IT1293069B1 (en) 1997-07-01 1997-07-01 INHIBITORS OF NF-KB AS HSF ACTIVATORS AND PROTEIN INDUCTORS FROM THERMAL SHOCK
ITRM97A000392 1997-07-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US53339900A Continuation-In-Part 1996-01-14 2000-03-22

Publications (2)

Publication Number Publication Date
WO1999001117A2 WO1999001117A2 (en) 1999-01-14
WO1999001117A3 true WO1999001117A3 (en) 1999-04-01

Family

ID=11405151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004066 WO1999001117A2 (en) 1996-01-14 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins

Country Status (6)

Country Link
EP (1) EP1003492A2 (en)
JP (1) JP2002507981A (en)
AU (1) AU8854598A (en)
CA (1) CA2294764A1 (en)
IT (1) IT1293069B1 (en)
WO (1) WO1999001117A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289250B1 (en) 1996-12-13 1998-09-29 Consiglio Nazionale Ricerche USE OF 2 CYCLOPENTEN 1-ONE AND ITS DERIVATIVES AS INHIBITORS OF THE NF-KB FACTOR
JP2003089636A (en) * 2001-07-12 2003-03-28 Hirofumi Kai Agent for suppressing synthesis and function of heat shock protein
JP5697879B2 (en) * 2010-03-12 2015-04-08 株式会社再春館製薬所 Heat shock protein expression inducer
JP2015042675A (en) * 2014-11-13 2015-03-05 株式会社再春館製薬所 Expression inducer for heat shock protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954519A (en) * 1987-04-28 1990-09-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
DE4311835A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Method for inhibiting gene transcription

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954519A (en) * 1987-04-28 1990-09-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
DE4311835A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Method for inhibiting gene transcription

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AMICI ET AL.: "Selective Inhibition of Virus Protein Synthesis by Prostaglandin A1: a Translational Block Associated with HSP70 Synthesis.", J. VIROL., vol. 68, 1994, pages 6890 - 6899, XP002091954 *
BREITHAUPT T B ET AL: "The suppression of T cell function and NF ( kappa ) B expression by serine protease inhibitors is blocked by N-acetylcysteine.", CELLULAR IMMUNOLOGY, (1996 OCT 10) 173 (1) 124-30. JOURNAL CODE: CQ9. ISSN: 0008-8749., United States, XP002091953 *
CHEN F ET AL: "Dependence and reversal of nitric oxide production on NF - kappa B in silica and lipopolysaccharide-induced macrophages.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1995 SEP 25) 214 (3) 839-46. JOURNAL CODE: 9Y8. ISSN: 0006-291X., United States, XP002092230 *
CONANT K ET AL: "Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF - kappa B binding and protein kinase C activity in primary human astrocytes.", JOURNAL OF VIROLOGY, (1996 MAR) 70 (3) 1384-9. JOURNAL CODE: KCV. ISSN: 0022-538X., United States, XP002092234 *
DENKO, NICHOLAS C. ET AL: "Protease inhibitor TPCK represses Ha-ras (Val12) transformation and nuclear factor-.kappa. B activation", INT. J. ONCOL. (1997), 10(5), 895-900 CODEN: IJONES;ISSN: 1019-6439, XP002092231 *
FINCO ET AL.: "Inducible phosphorylation of IkappaBalpha is not sufficient for its dissociation from NF-kappaB and is inhibited by protease inhibitors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, XP002091955 *
GUESDON F ET AL: "Interleukin 1-induced phosphorylation of MAD3, the major inhibitor of nuclear factor kappa B of HeLa cells. Interference in signalling by the proteinase inhibitors 3,4-dichloroisocoumarin and tosylphenylalanyl chloromethylketone.", BIOCHEMICAL JOURNAL, (1995 APR 1) 307 ( PT 1) 287-95. JOURNAL CODE: 9YO. ISSN: 0264-6021., ENGLAND: United Kingdom, XP002091957 *
NAKAGAWA, HIDEO ET AL: "Effect of proteinase inhibitors having antiinflammatory activity on gelatinase, elastase, and cathepsin G isolated from rat polymorphonuclear leukocytes", J. PHARMACOBIO-DYN. (1982), 5(5), 319-27 CODEN: JOPHDQ;ISSN: 0386-846X, XP002091952 *
ROSSI A ET AL: "INHIBITION OF NUCLEAR FACTOR KB BY PROSTAGLANDIN A1: AN EFFECT ASSOCIATED WITH HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 2, 21 January 1997 (1997-01-21), pages 746 - 750, XP002069382 *
SCHNEBLI H P: "GROWTH INHIBITION OF TUMOR CELLS BY PROTEASE INHIBITORS CONSIDERATION OF THE MECHANISMS INVOLVED.", CLARKSON, BAYARD AND RENATO BASERGA (ED.). COLD SPRING HARBOR CONFERENCES ON CELL PROLIFERATION, VOL. 1. CONTROL OF PROLIFERATION IN ANIMAL CELLS. XIII+1029P. ILLUS. COLD SPRING HARBOR LABORATORY: PO BOX 100, COLD SPRING HARBOR, N.Y. 11724, U.S.A. (1, XP002092232 *
WU, MIN ET AL: "Inhibition of NF -. kappa. B /Rel induces apoptosis of murine B cells", EMBO J. (1996), 15(17), 4682-4690 CODEN: EMJODG;ISSN: 0261-4189, XP002092233 *
YANG X ET AL: "Proteinases in renal cell death.", JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, (1996 JUL) 48 (4) 319-32. JOURNAL CODE: KAA. ISSN: 0098-4108., United States, XP002091956 *
ZHIRNOV, O. P. ET AL: "Alphavirus replication in cultured cells and infected animals is inhibited by antiproteinase agents", ANTIVIRAL RES. (1986), 6(5), 255-65 CODEN: ARSRDR;ISSN: 0166-3542, XP002092229 *

Also Published As

Publication number Publication date
WO1999001117A2 (en) 1999-01-14
CA2294764A1 (en) 1999-01-14
JP2002507981A (en) 2002-03-12
ITRM970392A0 (en) 1997-07-01
AU8854598A (en) 1999-01-25
EP1003492A2 (en) 2000-05-31
IT1293069B1 (en) 1999-02-11
ITRM970392A1 (en) 1999-01-01

Similar Documents

Publication Publication Date Title
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
AU5970298A (en) Dithiolan derivatives, their preparation and their therapeutic effect
EP1589017A3 (en) 12,13-modified epothilone derivatives
AU5704594A (en) Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU4383397A (en) Hetaroyl derivatives
HUP9601559A3 (en) Heterocyclic ring-fused pyrimidine derivatives, pharmaceutical compositions containing the same and intermediates
AU5013100A (en) Maize rs81 promoter and methods of use thereof
AU2272197A (en) Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
AU2467297A (en) New benzimidazole derivatives with antihistaminic activity
AU4589297A (en) Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
AU3162695A (en) Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
IL132967A0 (en) 3-Substituted 3,4-dihydro-thieno¬2,3-d¾pyrimidine derivatives and production and use of the same
AU2002223647A1 (en) Aryl-substituted indirubin derivatives, the production thereof and use of the same
EP1380586A3 (en) Photoactive benzoporphyrin derivatives
IL127689A (en) Acryloyl substituted distamycin derivatives, process for preparing them and their use for the manufacture of antitumor and antiviral agents
PL329878A1 (en) Derivatives of distamycin, method of obtaining them and their application as anticarcinogenic and antiviral agents
AU3775700A (en) Manufacture of hollow metallic articles
AU2003249713A1 (en) 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
WO1999001117A3 (en) Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
HUP9800697A3 (en) Dermatological use of vitamin d derivatives, new vitamin d derivatives, process for producing them and intermediates
WO1998025593A3 (en) 2-cyclopenten-1-one and its derivatives as inhibitors of the nf-kb factor
AU3420099A (en) Process for the production of purine derivatives and intermediates therefor
PL327686A1 (en) Derivatives of @-amino 5,6-dichlorobenzimidazole exhibiting antiviral activity
EP0832641A3 (en) Derivatives of bezoxazole useful as uv stabilizers
AU3467697A (en) 3'-oximino-2',3'-dideoxynucleosides and derivatives of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09446731

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2294764

Country of ref document: CA

Ref document number: 2294764

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998940106

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998940106

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998940106

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载